Of particular significance, the synergistic integration of anti-PD-1/PD-L1 antibodies with other therapeutic modalities has emerged as a robust and efficacious strategy in the comprehensive management of HCC [39]. Here, PDCD1 is linked to hepatocellular carcinoma.